If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 8 of 8
A Multi-Center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects with Relapsed and/or Refractory Diffuse Large B
Objective
Phase II MB-CART2019.1 for R/R DLBCL
Protocol No
MILTENYI-MB-CART2019-1-DLBCL
Categories
A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
Objective
A phase 1 Study evaluating NX-5948, a BTK Degrader in Adults with Relapsed Refractory B-cell Malignancies
Protocol No
NURIX-NX-5948-301
Categories
Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients with Relapsed and/or Refractory B Cell Malignancies
Objective
Study of tandem, bispecific anti-CD19 anti-CD20 CAR-T cells for Patients with Relapsed and/or Refractory B Cell Malignancies
Protocol No
IIT-SHAH-IL7-IL15-CD20-19
Categories
An Open-label-Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22 Directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants with Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CAR T-
Objective
A Phase 2 Study of CRG-022 in Patients with R/R B Cell Lymphoma after CD19-Directed Car-T Therapy
Protocol No
CARGO-CRG-022-101-LBCL
Categories
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Objective
A Phase 2 Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis
Protocol No
NMDP-CIBMTR-OPTIMIZE
Categories
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Objective
Study Evaluating Safety and Efficacy of JCAR017 in Subject with rrCLL or SLL
Protocol No
JUNO-017004-TRANSCEND-CLL
Categories
A Open-label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of Epcoritamab and Rituximab for Patients with Untreated Follicular Lymphoma (FL)
Objective
A phase 2 study of Epcoritamab and Rituximab for first-line treatment of follicular lymphoma.
Protocol No
DFCI-22-702
Categories
A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma
Objective
To find out if this approach is better or worse than the usual approach for DLBCL patients receiving CAR T-cell therapy. The usual approach for Relapsed/Refractory DLBCL patients is follow-up visits with no further therapy.
Protocol No
SWOG-S2114
Categories